Calculators

401k Retirement Calculator Mortgage Calculator

New

Student Loan Calculator Auto Loan Calculator

Education

How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990)

HKEX:6990

6990

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Stock Price & Analysis

0 Followers

6990 Stock Chart & Stats

Advanced Chart >

Day’s RangeHK$0 - HK$0

52-Week RangeHK$62.00 - HK$195.00

Previous CloseHK$148.7

Volume270.36K

Average Volume (3M)451.00K

Market Cap

HK$33.14B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.90

Next Earnings

Aug 28, 2024

EPS Estimate

-HK$1.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.91

Shares OutstandingN/A

10 Day Avg. VolumeN/A

30 Day Avg. Volume450,995

Standard DeviationN/A

R-SquaredN/A

AlphaN/A

Financial Highlights & Ratios

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

Price to Cash Flow (P/CF)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

HK$246.13

Price Target Upside65.52% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H News

PremiumCompany Announcements

Kelun-Biotech Commits to RMB370 Million in BOCOM Deposits

18d ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech Procures New Equipment

25d ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech’s RMB220M Wealth Management Move

26d ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech Plans Full H Share Circulation

1M ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech Shareholders Approve AGM Resolutions

1M ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech Announces New Board Structure

1M ago

6990

PremiumCompany Announcements

Kelun-Biotech’s Novel Cancer Drug Enters Clinical Trials

1M ago

6990

PremiumCompany Announcements

Sichuan Kelun-Biotech Sets AGM Registration Dates

2M ago

6990

See More HK:6990 News >

Options Prices

Currently, No data available

---

Ownership Overview

0.00%

Insiders

0.56% Mutual Funds

0.04% Other Institutional Investors

99.40% Public Companies and

Individual Investors

Detailed Ownership Overview >

6990 FAQ

What was Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$62.00 and its highest was HK$195.00 in the past 12 months.

What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s market cap?

Currently, no data Available

When is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date is Aug 28, 2024 which is in 36 days.

How were Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H released its earnings results on Mar 25, 2024. The company reported -HK$2.657 earnings per share for the quarter, missing the consensus estimate of -HK$1.468 by -HK$1.189.

Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H overvalued?

According to Wall Street analysts Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H pay dividends?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.

What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate is -HK$1.16.

How many shares outstanding does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H have?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 130,273,010 shares outstanding.

What happened to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H reported an EPS of -HK$2.657 in its last earnings report, missing expectations of -HK$1.468. Following the earnings report the stock price went up 4.701%.

Which hedge fund is a major shareholder of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?

Currently, no hedge funds are holding shares in HK:6990

---

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Stock Smart Score

Unlock Smart Score

Analyst Consensus

Moderate Buy

Average Price Target:
HK$246.13 (65.52% Upside)

Technicals

Top Smart Score Stocks >

6990 Stock 12 Month Forecast

Average Price Target

HK$246.13

▲(65.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"71":"HK$71","115":"HK$115","159":"HK$159","203":"HK$203","247":"HK$247"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":246.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">HK$246.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":246.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">HK$246.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":246.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">HK$246.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[71,115,159,203,247],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2023","6":"Jan<br/>2024","9":"Apr<br/>2024","12":"Jul<br/>2024","25":"Jul<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,163.4,169.76384615384615,176.1276923076923,182.49153846153845,188.85538461538462,195.21923076923076,201.58307692307693,207.94692307692307,214.31076923076924,220.67461538461538,227.03846153846155,233.4023076923077,239.76615384615383,{"y":246.13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,163.4,169.76384615384615,176.1276923076923,182.49153846153845,188.85538461538462,195.21923076923076,201.58307692307693,207.94692307692307,214.31076923076924,220.67461538461538,227.03846153846155,233.4023076923077,239.76615384615383,{"y":246.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,163.4,169.76384615384615,176.1276923076923,182.49153846153845,188.85538461538462,195.21923076923076,201.58307692307693,207.94692307692307,214.31076923076924,220.67461538461538,227.03846153846155,233.4023076923077,239.76615384615383,{"y":246.13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":77.1,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":76.5,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":76.6,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":83,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":89.8,"date":1700784000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.75,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.5,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.9,"date":1709856000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.3,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.3,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.4,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Baidu, Inc. Class A

―

1167

Jacobio Pharmaceuticals Group Co., Ltd.

―

Compare HK:6990 Stocks >

Best Analysts Covering 6990

1 Year

Chen ChenUBS

1 Year Success Rate

1/1 ratings generated profit

1 Year Average Return

+74.10%

initiated a buy rating 8 months ago

Copying Chen Chen's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +74.10% per trade.

Best Analyst Covering >

Popular Stocks

---

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing